TrialTracker_MD said:

MASH prevalence in GLP-1 users 6 is not that straightforward in my experience

This is exactly right. TrialTracker_MD articulated what I have been trying to explain to my friends for months. The MASH prevalence in GLP-1 aspect is what made the difference for me.

Reading this thread on MASH prevalence in GLP-1 hits close to home. Dad of 2 checking in — I started at 285 lbs and felt like I would tried everything.

11 months on tirz and I am a different person. Not just the 60 lbs lost — my energy, my mood, my relationship with food. All transformed.

If you are on the fence about MASH prevalence in — take the leap. It was the best health decision I have ever made. ❤️

anna.melb_AU — that is really helpful context on MASH prevalence in GLP-1. Follow-up question: how long did you wait before increasing your dose?

I am in a similar situation (week 4) and trying to set realistic expectations.

To answer DanielChem_CHI's question specifically:

From a clinical standpoint, MASH prevalence in GLP-1 users is a reasonable concern that deserves a thorough answer.

The short answer: the evidence supports this approach for most patients.

The longer answer involves reviewing the specific clinical trial data relevant to your question, which I am happy to elaborate on if helpful.

Bookmarked 📌 The MASH prevalence in info in this thread is essential. Coming back to this for sure.